Heart failure (HF), the end-stage of cardiovascular disease, is a growing public health burden, with high morbidity and mortality worldwide. The multidimensional nature of Heart failure is related to multiple cardiometabolic risk factors, including genetic, behavioral and environmental factors, encompassing a range of lifestyle-related conditions, e.g., smoking, hypertension, hyperglycemia/insulin resistance, dyslipidemia, overweight/obesity, and chronic vascular inflammation.
In its nature, cardiometabolic dysfunction plays an important role in the incident and prognosis of Heart failure. However, our understanding of the association between cardiometabolic dysfunction and HF is still limited, the underlying risk factors, novel biomarkers and associated pathophysiological mechanisms remain to be further investigated. For example, whether novel risk factors such as cytokines, inflammatory factors, secreted frizzled related proteins, are causally associated with the incident of cardiometabolic dysfunction in HF, or they are just the epiphenomenon of other cardiometabolic factors related to cardiovascular disease? Are there any novel biomarkers (non-coding RNA, exosomes, adipokines) associated with cardiometabolic dysfunction in HF, and playing a role in improving the management of HF?
As the prevalence of HF continues to increase worldwide, it is of critical importance to gain further insights into the interaction among risk factors, biomarkers, as well as the prevention and treatment strategies of cardiometabolic dysfunction and HF. In this Research Topic, we would like to create a forum for current advances on risk factors, novel biomarkers, cellular and physiological mechanisms in cardiometabolic dysfunction associated with HF, as well as pathophysiological and clinical consequences of HF induced by metabolic dysregulation. We welcome manuscripts focusing on the cardiovascular risk-factor-related vascular/myocardial injury and its sensitive indicators, such as new molecular biomarkers. We also welcome clinical or experimental studies evaluating the efficacy of potential therapeutics against metabolic syndrome, obesity, NAFLD, diabetes and CVD in relation to HF.
Topics of interest include but are not limited to:
1) Novel cardiometabolic biomarkers (e.g. cytokines, endothelial granules, inflammatory factors, endothelial progenitor cells, microRNA, circRNA, lncRNA) in the pathogenesis and pathophysiological mechanisms in HF.
2) Novel cardiometabolic risk factors and their cellular and molecular mechanisms involved in HF.
3) New strategies for elevating the development and progression of cardiometabolic dysfunction associated with HF.
4) The molecular mechanisms involved in the development of metabolic pathways in cardiovascular disease, especially for HF.
5) Insulin resistance, metabolic dysfunction and diabetic associated pro-inflammatory / pro-thrombotic state in HF.
6) Other significant advances in evaluating or treating cardiometabolic dysfunction in HF.
Heart failure (HF), the end-stage of cardiovascular disease, is a growing public health burden, with high morbidity and mortality worldwide. The multidimensional nature of Heart failure is related to multiple cardiometabolic risk factors, including genetic, behavioral and environmental factors, encompassing a range of lifestyle-related conditions, e.g., smoking, hypertension, hyperglycemia/insulin resistance, dyslipidemia, overweight/obesity, and chronic vascular inflammation.
In its nature, cardiometabolic dysfunction plays an important role in the incident and prognosis of Heart failure. However, our understanding of the association between cardiometabolic dysfunction and HF is still limited, the underlying risk factors, novel biomarkers and associated pathophysiological mechanisms remain to be further investigated. For example, whether novel risk factors such as cytokines, inflammatory factors, secreted frizzled related proteins, are causally associated with the incident of cardiometabolic dysfunction in HF, or they are just the epiphenomenon of other cardiometabolic factors related to cardiovascular disease? Are there any novel biomarkers (non-coding RNA, exosomes, adipokines) associated with cardiometabolic dysfunction in HF, and playing a role in improving the management of HF?
As the prevalence of HF continues to increase worldwide, it is of critical importance to gain further insights into the interaction among risk factors, biomarkers, as well as the prevention and treatment strategies of cardiometabolic dysfunction and HF. In this Research Topic, we would like to create a forum for current advances on risk factors, novel biomarkers, cellular and physiological mechanisms in cardiometabolic dysfunction associated with HF, as well as pathophysiological and clinical consequences of HF induced by metabolic dysregulation. We welcome manuscripts focusing on the cardiovascular risk-factor-related vascular/myocardial injury and its sensitive indicators, such as new molecular biomarkers. We also welcome clinical or experimental studies evaluating the efficacy of potential therapeutics against metabolic syndrome, obesity, NAFLD, diabetes and CVD in relation to HF.
Topics of interest include but are not limited to:
1) Novel cardiometabolic biomarkers (e.g. cytokines, endothelial granules, inflammatory factors, endothelial progenitor cells, microRNA, circRNA, lncRNA) in the pathogenesis and pathophysiological mechanisms in HF.
2) Novel cardiometabolic risk factors and their cellular and molecular mechanisms involved in HF.
3) New strategies for elevating the development and progression of cardiometabolic dysfunction associated with HF.
4) The molecular mechanisms involved in the development of metabolic pathways in cardiovascular disease, especially for HF.
5) Insulin resistance, metabolic dysfunction and diabetic associated pro-inflammatory / pro-thrombotic state in HF.
6) Other significant advances in evaluating or treating cardiometabolic dysfunction in HF.
